Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL

Summary

This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected allogeneic γδT-cells in patients with high risk, relapsed CD19+ haematological malignancies.

Timeline

Start

2017-10

Primary completion

2019-04

Completion

2020-04

Drugs

Indications